Raloxifene for Breast Cancer
From New Treatment Wiki
Lifetime exposure to estrogens correlates with the incidence of breast cancer in women at risk. Transgenic mice with aromatase overexpression are more susceptible to carcinogen-induced breast cancer. Blockade of receptor-mediated proliferation is believed to be the mechanism whereby the selective ER modulators, such as tamoxifen and raloxifene, prevent breast cancer in women. An alternate hypothesis postulates that estrogens can be enzymatically converted via cytochrome P450 1B1 to catechol-estrogens and then to estrogen-quinones.
